XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue $ 36,161 $ 60,827  
Constrained for Future Recognition [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue 2,100 2,300  
Product Revenue, Net [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue 24,161 18,881  
China [Member] | Product Revenue, Net [Member]      
Contract with Customer, Liability [Abstract]      
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration 300    
AstraZeneca Agreements [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 175,326   $ 175,646
AstraZeneca Agreements [Member] | China [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 22,500    
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member]      
Contract with Customer, Liability [Abstract]      
Reductions to gross accounts receivable $ 2,200 $ 500